You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Non-Invasive Oropharynx Appliance to Maintain Airway Patency

    SBC: ANEMED LLC            Topic: NHLBI

    Obstructive Sleep Apnea (OSA) is a serious condition that affects about 4% of the population. During sleep, the tongue can fall into the oropharynx and occlude the airways Patients with this condition suffer many instances of apneas (complete cessation of breathing) and hypopneas (period of abnormally low respiratory rate). The apnea- hypopnea index (AHI) gives the number of such episodes per hour ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Regenerative Therapy for Corneal Endothelial Dystrophies and Injuries

    SBC: RASHMIVU LLC            Topic: N

    Summary Worldwide, only 1 out of 70 patients with corneal endothelial dystrophies and injuries receive a corneal transplant due to the limited corneal donor pool, the need for advanced surgical facilities and talent, and expense. RashmiVu is developing a stem cell based regenerative technology that addresses this large unmet global need through a paradigm shift, wherein treatment could be as simpl ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Development of CA-IL-12 for Triple Negative Breast Cancer

    SBC: CYTONUS THERAPEUTICS, INC.            Topic: 102

    Among the 1.7 million new cases of breast cancer diagnosed globally each year, 15-20% are triple-negative breast cancer (TNBC), which has an aggressive phenotype with high metastatic capability and poor prognosis. However, current therapeutics for TNBC have unpredictable efficacy, poor biomarker availability, serious side effects, and the development of treatment resistance. The goal of this propo ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Hybrid nanoparticles as highly efficient photosensitizers for the treatment of topical bacterial infections

    SBC: Alph Technologies, LLC            Topic: NIAID

    PROJECT SUMMARYAntimicrobial drug resistance is one of the biggest threats to public health globally. Developing new antibiotics alone cannot fully address the problem, as antimicrobial resistance will be developed eventually and inevitably to conventional antibiotics. Therefore, alternative non-antibiotic approaches are urgently needed to meet this global challenge. Antimicrobial photodynamic ina ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Detecting Arch Instability in Charcot Neuropathy

    SBC: Innovative Scientific Solutions, Inc            Topic: NIDDK

    AbstractCharcot neuropathy (CN) is a serious complication resulting from poorly controlled diabetes and peripheral neuropathy that leads to the collapse, and ultimately the breakdown, of the midfoot. Charcot occurs in approximately 0.08% of the general diabetic population, however the prevalence increases to 13% in high-risk diabetic patients [1,2] and even 35% in patients with polyneuropathy in i ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government